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Abstract
Shwachman-Diamond Syndrome (SDS) is a rare inherited disease caused by mutations in the SBDS gene. Hematopoietic
defects, exocrine pancreas dysfunction and short stature are the most prominent clinical features. To gain understanding of
the molecular properties of the ubiquitously expressed SBDS protein, we examined its intracellular localization and mobility
by live cell imaging techniques. We observed that SBDS full-length protein was localized in both the nucleus and cytoplasm,
whereas patient-related truncated SBDS protein isoforms localize predominantly to the nucleus. Also the nucleo-
cytoplasmic trafficking of these patient-related SBDS proteins was disturbed. Further studies with a series of SBDS mutant
proteins revealed that three distinct motifs determine the intracellular mobility of SBDS protein. A sumoylation motif in the
C-terminal domain, that is lacking in patient SBDS proteins, was found to play a pivotal role in intracellular motility. Our
structure-function analyses provide new insight into localization and motility of the SBDS protein, and show that patient-
related mutant proteins are altered in their molecular properties, which may contribute to the clinical features observed in
SDS patients.
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Introduction
Shwachman-Diamond Syndrome (SDS) was first described in
1964 and is a rare, hereditary disease, characterized by pancreatic
insufficiency and bone marrow failure.[1,2]. The most prominent
hematopoietic defect is neutropenia, which is often accompanied
by thrombocytopenia and anemia [3–5]. The neutropenia,
together with the reported neutrophil chemotaxis defects in SDS
patients, results in an increased risk of recurrent infections [5,6].
Additionally, SDS patients have a cumulative risk of 20 to 36% of
developing myeloid dysplasia (MDS) and/or acute myeloid
leukemia (AML) at the age of 20 or 30 years [7].
In 2003, identification of mutations in the SBDS gene located at
chromosome 7 in most SDS patients, provided the molecular basis
for further investigations to the underlying mechanisms defective
in SDS [8]. To date, several mutations have been identified but
the two most common mutations are the consequence of 183–184
TA.CT and 258+2T.C genomic changes [5,8–10]. These
mutations are located in exon 2 and intron 2, and result in a
premature stop-codon (K62X) and a frameshift mutation resulting
in a stopcodon (C84fsX3) respectively [8].
Structural analysis revealed that the SBDS protein contains
three domains, an N-terminal conserved FYSH domain, central
helical domain and C-terminal domain with homology to an
RNA-binding motif [11,12]. The yeast ortholog of SBDS, Sdo1,
was shown to interact with rRNA-processing proteins and play a
role in pre-60S ribosome transport [11,13]. In human cells SBDS
was shown to interact with hsNip7, a protein required for 27S pre-
rRNA cleavage and 60S subunit biogenesis [14]. Additionally, in
human HeLa cells SBDS was reported to be localized to the
nucleoli, a nuclear subcompartment important for ribosome
processing. Altogether, these data implicate SBDS in ribosome
maturation and rRNA processing. [11–16]. Besides a role in
ribosome/RNA-related function, SBDS has been implicated in
neutrophil chemotaxis and more recently SBDS has been shown
to co-localize with the mitotic spindle [17,18] indicating a
potential role in chromosome segregation during mitosis. Hence,
the data published so far suggest that SBDS is a multifunctional
protein and proper localization and/or intracellular mobility
dynamics of the SBDS protein are consequently important for
fulfilling its various cellular functions.
For many proteins, including signaling proteins and transcrip-
tion factors, it has been shown that intracellular localization has
important consequences for their interaction partners and hence
their cellular function. Aberrant localization and/or disrupted
regulation have been reported to result in and/or to contribute to
pathological conditions, including cancer and excessive inflam-
matory reactions [19–22]. Protein function and localization is
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protein modifications. Hematological abnormalities, including
neutropenia and leukemia, can also be caused by gene mutations
that result in altered proteins with an aberrant intracellular protein
localization and function. For example, mutations in the RPS19
gene, as observed in Diamond-Blackfan anemia patients, result in
aberrant non-nucleolar localization and ribosomal defects [23–
25]. Also, mutations in the NPM1 gene, observed in 30% of the
patients suffering from acute myeloid leukemia (AML), result in
aberrant cytoplasmic protein localization that may contribute to
leukemogenesis through disruption of the p14(ARF)- MDM2-p53
pathway and centrosomal duplication [26–28].
Similar to NPM1 and RPS19, the SBDS protein has been
implicated to play an important role in ribosome function or
assembly and defects in all three genes are observed in patients
suffering from either neutropenia or leukemia. This raises the
question whether patient-derived SBDS protein variants, similar to
mutated NPM1 and RPS19 proteins, have an altered intracellular
localization and possibly also different mobility properties.
To investigate this,weperformedintracellularlocalizationstudies
and live cell imaging with GFP- and HA-tagged SBDS proteins.
Our studies reveal that the truncated patient-related SBDS proteins
(SBDS-patient) preferentially localized to the nucleus and display
increased nucleo-cytoplasmic trafficking as compared to full-length
SBDS (SBDS-FL). Further studies allowed us to map in more detail
the critical SBDS regions important for intracellular localization
and trafficking and have revealed that the C-terminus of the SBDS
protein is crucial for nucleo-cytoplasmic shuttling, which may be
regulated by SUMOylation. Inhibition of cellular transcription or
translation resulted in enhanced nucleo-cytoplasmic shuttling of the
expressed SBDS proteins, supporting the presumed role of SBDS in
ribosomal function. Altogether, our study provides novel genotype-
function relationships and molecular insight into the function of
SBDS in the Shwachman-Diamond Syndrome.
Results
Subcellular localization of SBDS
To gain more insight into the cellular and molecular function of
SBDS, we examined the subcellular localization of the full length
GFP- and HA-tagged SBDS-FL protein. Also, we introduced
translational stopcodons at K62, at C84 or at R218 to mimic SDS
patient SBDS truncated proteins (Fig. 1A). Western blot analysis of
transiently transfected HeLa cells with these GFP-tagged or HA-
tagged SBDS constructs showed that these proteins are expressed
and have the expected molecular sizes (Fig. 1B; Suppl. Fig. S1).
Immunofluorescence studies revealed that GFP-SBDS-FL local-
ized both to the nucleus and the cytoplasm, with higher SBDS
protein levels in the nucleus (Fig. 1C). Quantification of the protein
levels in these cellular sub-compartments revealed that SBDS-FL
protein levels are 3-fold higher in the nucleus as compared to the
cytoplasm (Fig. 1D). In contrast, examination of the two most
common patient-related SBDS mutations, (SBDS-K62 and SBDS-
C84) showed that these proteins predominantly localized to the
nuclear compartment with very low cytoplasmic staining (Fig. 1C).
Thiswassupportedbyquantification ofthenuclearandcytoplasmic
protein expression levels for these SBDS patient-related proteins,
showing that the nuclear SBDS protein levels were 5-fold higher
compared to the cytoplasm (Fig. 1D). For HA-tagged SBDS
proteins and endogenous SBDS similar results were obtained
(Suppl. Fig. S1, and data not shown), indicating that cellular
distribution was not significantly affected by fusion to the GFP.
Interestingly, the SDS-related SBDS-R218 mutant which lacks only
a small part of the C-terminus [10], localized in a similar manner as
the severely truncated SBDS-K62 and SBDS-C84 proteins. These
data show that GFP-SBDS-FL has a significantly different
subcellular distribution as compared to these patient-related SBDS
protein isoforms, indicating functional differences between these
SBDS proteins. Moreover, these data suggest that the SBDS C-
terminus plays an important role in cytoplasmic localization.
Patient-related SBDS proteins show enhanced nuclear
import and export
To examine whether changes in intracellular trafficking
contributed to the aberrant localization of the truncated GFP-
tagged SBDS patient-related proteins, we performed live cell
imaging experiments, including Fluorescence Recovery After
Photobleaching (FRAP) and Fluorescence Loss in Intensity after
Photobleaching (FLIP) experiments.
First,FRAPanalysisofGFP-SBDS-FLwithinthenucleusandthe
cytoplasm revealed that GFP-SBDS-FL protein levels were
minimally recovered to the nucleus within 10 minutes post-
bleaching. GFP-SBDS-FL distribution remained similar to the
moment immediately after bleaching (3% of original intensity;
Fig. 2A/C and Suppl. Fig. S2A). In contrast to GFP-SBDS-FL, we
observed that free GFP was rapidly redistributed from the
cytoplasm to the nucleus after nuclear bleaching. Within 5–6 min
GFP was distributed intracellular in a similar fashion as pre-
bleaching (Fig. 2C), which is consistent with the rate of free GFP
mobility previously reported by others [29]. To further investigate
the striking lack of nuclear import of the GFP-SBDS-FL protein, we
examined the possibility that GFP-SBDS-FL nuclear import and
export was hampered due to immobility in either the cytoplasm or
the nucleus as the results of protein-protein interactions. Therefore,
we bleached part of the cytoplasm and monitored fluorescence
recovery. Within 2 minutes post-bleach full cytoplasmic recovery at
the bleach area was observed, showing that GFP-SBDS-FL is
mobile within the cytoplasm (Suppl. Fig. S2B), although the
recovery kinetics of GFP-SBDS-FL is slower than GFP (data not
shown). Similar experiments were performed to examine SBDS
nuclear mobility. We observed that also within the nucleus GFP-
SBDS-FL was mobile (data not shown). To examine whether
eventually GFP-SBDS-FL fluorescence could be recovered after
nuclear bleaching, we performed imaging for several hours after
bleaching. We observed that GFP-SBDS-FL fluorescence in the
nucleus recovers only after 1–2 hours post nuclear bleaching,
indicating that GFP-SBDS-FL nucleo-cytoplasmic transport under
steady state conditions takes place at an extremely slow rate (n=17
cells; 2 independent experiments; data not shown).
Next, we examined the mobility of the fluorescent SBDS
patient-related proteins. GFP-SBDS-K62 and GFP-SBDS-C84
showed rapid and maximal nuclear recovery (61–70% of the
original nuclear intensity) within 10 minutes after photobleaching
(Fig. 2B/C, and data not shown). Similar to GFP-SBDS-FL, the
patient-related GFP-SBDS-K62 and GFP-SBDS-C84 proteins
were mobile within the cytoplasm and nucleus (data not shown).
Interestingly, the GFP-SBDS-R218 protein recovered at a slower
rate than GFP-SBDS-C84 and at later time points recovery was
severely hampered. This resulted in an only partial nuclear
recovery of the fluorescence for GFP-SBDS-R218. In accordance
with this, we observed that GFP-SBDS-R218 was partially
immobile in the cytoplasm (data not shown).
To determine whether GFP-SBDS-FL and the patient-related
SBDS proteins could be transported from the nucleus to the
cytoplasm, we performed FLIP experiments. Interestingly, over a
period of 10 minutes GFP-SBDS-FL fluorescence in the nucleus
decreased to 80% of the original nuclear fluorescence intensity
(Fig. 2D/F), indicating that GFP-SBDS-FL is able to cross the
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nuclear export do necessarily not take place with similar kinetics
and/or similar conditions. Similar to GFP-SBDS-FL, although
with slightly increased kinetics, GFP-SBDS-C84 (Fig. 2E/F) and
GFP-SBDS-K62 (not shown) fluorescence in the nucleus was also
clearly decreased upon repeated cytoplasmic bleaching. After
10 minutes the GFP-SBDS-C84 and GFP-SBDS-K62 fluo-
rescence intensity was decreased to approximately 60% of the
original fluorescence intensity (Fig. 2E/F). In contrast to the
GFP-SBDS (truncated) proteins, free GFP fluorescence in the
nucleus was rapidly lost to 30% of its original intensity
upon repeated bleaching of the cytoplasm over a period of 10
minutes (Fig. 2F).
To exclude the possibility that nuclear import and export of
GFP-SBDS-FL was hampered due to molecular size constraints,
we generated a GFP-GFP fusion protein which has a comparable
molecular weight as GFP-SBDS-FL. As shown in Figure 3E/F, the
GFP-GFP fusion protein was rapidly imported into and exported
from the nucleus, although import/export kinetics were slower
than the single free GFP (42% recovery in 10 minutes for nuclear
import of GFP-GFP). Furthermore, to exclude the possibility that
either SBDS protein expression levels or the position of the GFP-
tag disturbs localization and mobility to great extent, we examined
individual cells with different GFP-SBDS protein expression levels.
We observed that expression levels did not affect GFP-SBDS
protein isoform cellular behavior.
Figure 1. SDS-patient SBDS proteins are localized to the nucleus. (A) Schematic overview of the GFP-tagged SBDS constructs (B) Western
blot analysis shows that GFP-tagged SBDS proteins have the expected molecular sizes of 59 kDa, 36 kDa, 39 kDa and 54 kDa for the GFP-SBDS-FL,
GFP-SBDS-K62, GFP-SBDS-C84 and GFP-SBDS-R218 respectively. (C) Representative pictures of the intracellular localization of the GFP-tagged SBDS
proteins. Bottom panel shows the GFP fluorescence intensity plots measured as indicated in the corresponding cells in the top panel. (D) Average
ratio of the nuclear/cytoplasmic GFP fluorescence intensity for the different GFP-tagged constructs Asterisk indicates that the localization of the GFP-
SBDS-FL is statistically significant different (p,0.001) from the SDS-patient GFP-SBDS proteins. Error bar indicates s.e.m.(FL n=42 cells, K62 n=52
cells, C84 n=37 cells, R218 n=33 cells analysed in 3–5 independent experiments).
doi:10.1371/journal.pone.0020727.g001
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proteins which showed similar mobility behavior as the N-terminal
GFP-tagged SBDS proteins used in this study (data not shown).
Altogether, this indicates that molecular size, expression level or
the location of the GFP-tag does not seem to be the essential factor
in preventing GFP-SBDS-FL nuclear import.
Hence, our data show that GFP-SBDS-FL is minimally
imported into the nucleus under steady-state conditions, whereas
only low levels of GFP-SBDS-FL are exported from the nucleus to
the cytoplasm. In contrast, patient-related SBDS mutant proteins
are rapidly redistributed from the cytoplasm to the nucleus and
vice versa.
SBDS protein analysis reveals critical motifs for cellular
localization and trafficking
To further investigate the SBDS protein motifs and/or domains
that are involved in localization and mobility, we generated several
additional GFP-SBDS mutant proteins. First, GFP-SBDS N-
terminally truncated constructs lacking the first 62, 75 or 85 amino
acids were generated. These GFP-tagged artificial mutants are
complementary to the SDS patient-derived GFP-SBDS-K62 and
GFP-SBDS-C84 protein variants (Fig. 3A). Western blot analysis
showed that these proteins were expressed with the correct
molecular size (Fig. 3B). In contrast to the patient-related SBDS
proteins, these N-terminally truncated SBDS proteins were all
localized in both the nucleus and cytoplasm, in a similar manner
as GFP-SDBS-FL (Fig. 3C/D). Noteworthy is that the GFP-SBDS
D1–62 and GFP-SBDS D1–75 nuclear-cytoplasmic protein ratio
of 2 was significantly lower as compared to the GFP-SBDS-FL and
GFP-SBDS D1–85 nuclear-cytoplasmic ratio of approximately 3
(Fig. 3D).
These N-terminally truncated SBDS proteins showed clear
differences with the full-length SBDS protein with regard to their
intracellular trafficking behavior. GFP-SBDS D1–62, GFP-SBDS
Figure 2. SDS-patient SBDS proteins have different intracellular mobility characteristics compared to GFP-SBDS-FL. (A)
Representative GFP-SBDS-FL and (B) GFP-SBDS-C84-expressing cell for FRAP analysis prior to bleaching, at the moment of nuclear bleaching and
10 min post-bleach. (C) FRAP analysis showing the average nuclear/cytoplasmic GFP ratio for free GFP (black curve), GFP-SBDS-FL, GFP-SBDS-C84 and
GFP-SBDS-R218 (grey curves); 5–9 cells per construct in 2–3 independent experiments were analysed for 10 min recovery and 12–14 cells for 5 min
recovery in 3 independent experiments (not shown). (D) Representative GFP-SBDS-FL and (E) Representative GFP-SBDS-C84 expressing cell for FLIP
analysis prior to bleaching, at the moment of nuclear bleaching and 10 min post-bleach (F) FLIP analysis showing the average nuclear GFP intensity
for free GFP (black curve), GFP-SBDS-FL, GFP-SBDS-C84 and GFP-SBDS-R218; 7–11 cells per construct in 2–3 independent experiments were analysed.
doi:10.1371/journal.pone.0020727.g002
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trafficking properties than GFP-SBDS-FL. (A) Schematic overview of the GFP-tagged SBDS constructs. (B) Western blot analysis shows that GFP-
tagged SBDS proteins have the expected molecular sizes of 51 kDa, 49 kDa and 48 kDa for the GFP-SBDS D1–62, GFP-SBDS D1–75 and GFP-SBDS D1–
85 respectively. (C) Representative picture of the GFP-SBDS D1–85 protein. Bottom panel show the GFP fluorescence intensity plots measured as
indicated in the corresponding cells in the top panel. White bar represents 10 mm. (D) Average ratio of the nuclear/cytoplasmic GFP fluorescence
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the nucleus than the GFP-SBDS-FL protein (Fig. 3E; data not
shown). Nonetheless, the import rate was slower than that for
GFP-SBDS-K62 or GFP-SBDS-C84 proteins (Table 1). Subse-
quent FLIP experiments showed that these N-terminally truncated
SBDS proteins were exported from the nucleus to the cytoplasm at
almost similarly slow (GFP-SBDS D1–62, GFP-SBDS D1–75) or
even slower (GFP-SBDS D1–85) rates, when compared to GFP-
SBDS-FL. The increase in export rate together with the
significantly lowered nuclear-cytoplasmic ratio of the GFP-SBDS
D1–62 and D1–75 as compared to GFP-SBDS D1–85, suggest that
the protein region containing amino acids 75–85 is involved in
nuclear export, although in silico analysis did not reveal a consensus
nuclear export signal (NES) in this sequence.
Thus, these data show that the absence of the N-terminal part of
SBDS does not affect cytoplasmic SBDS localization to a great
extent, but strongly affects nuclear import under normal steady-
state conditions.
SBDS C-terminus dictates cytoplasmic localization
Our data indicated that the C-terminus of SBDS is required for
cytoplasmic localization and/or retention, since the full-length and
N-terminally truncated SBDS proteins were localized to the
nucleus and the cytoplasm, whereas the C-terminally truncated
patient-related SBDS protein isoforms predominantly localized to
the nucleus. In line with this, GFP-SBDS-R218, which lacks only
32 amino acids of the SBDS C-terminus, also showed a prominent
nuclear localization, indicating that the short stretch of amino
acids 218–250, contains a pivotal localization signal.
To explore this further, we generated the GFP-SBDS-L234
mutant, an SBDS protein lacking the last 16 C-terminal amino
acids and examined its localization and mobility properties. We
observed that GFP-SBDS-L234 and GFP-SBDS-FL have a similar
subcellular distribution (Fig. 4A/B), indicating that the region
between R218-L234 contains the essential nuclear localization
motif that results in the different distribution of GFP-SBDS-R218
as compared to GFP-SBDS-FL and GFP-SBDS-L234. However,
in contrast to the full-length protein, GFP-SBDS-L234 could be
transported in and out of the nucleus more rapidly, suggesting that
localization and mobility properties are not necessarily linked
(Fig. 4E/F).
To further explore the SBDS C-terminal localization and
mobility properties, we analysed the SBDS protein sequence in
silico for potential post-translational modification consensus
sequences. We observed several potential consensus sequences
(YKxE) for Small Ubiquitin-related Modifier (SUMO) protein
modification in the SBDS protein, including a SUMO consensus
sequence in the C-terminus at amino acid positions 225–227
(Fig 4C). Several studies have reported that sumoylation can affect
subcellular localization and protein function [30–35]. To explore
whether SBDS can be modified by SUMOylation, we transiently
expressed his-tagged SUMO-1 or his-tagged SUMO-2 together
with HA-SBDS-FL in HeLa cells and performed his-SUMO pull-
down assays. As shown in Figure 4D, Western blot analysis
revealed that HA-SBDS-FL can be sumoylated by SUMO-2, as
detected at an apparent molecular weight of 50 kDa on SDS-
PAGE, consistent with an increase of 17 kDa of SBDS-FL due to
the covalent binding of SUMO-2. As this protein band remains
absent for a pull-down with SUMO-1, SBDS seems to be
particularly sumoylated by SUMO-2. The 50 kDa sumoylated
SBDS protein band could not be detected in the protein input,
which suggests that only a small portion of the SBDS protein pool
is sumoylated, consistent with reports on other sumoylated
proteins [30–35]. These data thus reveal that SBDS can be
sumoylated by SUMO-2, supporting the idea that post-transla-
tional modification of SBDS plays a role in subcellular mobility.
Next, we generated two GFP-SBDS protein mutants in which
the C-terminal SUMO consensus site was disrupted. In the
GFP-SBDS-K225-226R mutant, the two adjacent lysine residues
are changed to arginine residues within the YKxE
consensus sequence, rendering this site unsuitable for SUMO
attachment at the lysine residues. Additionally, we generated a
Table 1. Overview of GFP-SBDS intracellular mobility.
Construct nuclear import nuclear export
GFP +++ +++
GFP-GFP ++ +++
GFP-SBDS-FL 2 6
SDS-patient mutations
GFP-SBDS-K62 +++ ++
GFP-SBDS-C84 +++ ++
GFP-SBDS-R218 6 (*) 6 (*)
C-terminal truncations
and mutations
GFP-SBDS-L234 ++ +
GFP-SBDS-K225-226R + +
GFP-SBDS-E227Q
N-terminal truncations
GFP-SBDS D1–62 + +
GFP-SBDS D1–75 + +
GFP-SBDS D1–85 + 6
Inhibitors
GFP-SBDS-FL+ actinomycinD 6 ++
GFP-SBDS-FL+ cyclohexamide 6 ++
Fluorescence recovery within 10 minutes: .50%=+++; 35–50%=++; 20–35%=+;
20–5%=6; ,5%=2.
Fluorescence loss within 10 minutes: .50%=+++; 35–50%=++; 20–35%=+;
,20%=6.
(*) GFP-SBDS-R218 is immobile in the cytoplasm and therefore nuclear import
and export could not be determined properly.
doi:10.1371/journal.pone.0020727.t001
intensity for the different GFP-tagged constructs. GFP-SBDSD1–62 and D1–75 are significantly more localized to the cytoplasm as compared to GFP-
SBDS D1–85 (p,0.001). Error bar indicates s.e.m. (FL n=42 cells, D1–62 n=32 cells, D1–75 n=28 cells, D1–85 n=42 cells in 3–4 independent
experiments). (E) FRAP analysis for nuclear import showing the average nuclear/cytoplasmic GFP ratio for GFP-GFP, GFP-SBDS-FL and GFP-SBDS D1–
85. In total 6 cells per construct in 2 independent experiments were analysed. (F) FLIP analysis for nuclear export showing the average nuclear GFP
intensity for GFP-GFP, GFP-SBDS-FL and GFP-SBDSD1–85. We analysed 7–11 cells per construct in 3 independent experiments.
doi:10.1371/journal.pone.0020727.g003
SBDS Domains Affect Protein Mobility
PLoS ONE | www.plosone.org 6 June 2011 | Volume 6 | Issue 6 | e20727GFP-SBDS-E227Q mutant in which the potential SUMO
consensus site in general was disrupted. Localization of the GFP-
SBDS-K225-226R protein was observed in the cytoplasm and
nucleus, similar as the GFP-SBDS-FL and GFP-SBDS-L234
proteins (Fig. 4A/B).
In the live cell-imaging experiments the GFP-SBDS-K225-
226R mutant behaved identical to GFP-SBDS-L234 protein,
suggesting that these two lysine amino acids are important for
SBDS intracellular mobility. To confirm the importance of this
site, we examined the intracellular localization and mobility of
GFP-SBDS-E227Q. These data showed that GFP-SBDS-E227Q
has similar intracellular localization and trafficking properties as
GFP-SBDS- K225-226R (Suppl. Fig. S3), further supporting the
idea that sumoylation plays a role in SBDS intracellular
trafficking.
Altogether these experiments show that SBDS can be post-
translationally modified by sumoylation, and that disruption of the
SUMO consensus site in the SBDS C-terminus has no effect on
intracellular localization, but does alter SBDS intracellular
mobility.
Physiological relevance of SBDS mobility and localization
Our data demonstrate that various SBDS protein regions
contribute to its localization and/or intracellular transport, but the
regulation involved in its motility within the cell remains unclear.
When both the N- and C-terminus are present, the nuclear import
and export of GFP-SBDS-FL are minimal under steady-state
conditions. The C-terminus, including a consensus SUMO site, is
important for regulating intracellular transport. Since SBDS has
been proposed by several studies to exhibit RNA-binding capacity
[10–15,36–38], we examined whether RNA-related cellular
processes such as transcription or translation could affect the
transport of full-length SBDS protein.
In the presence of actinomycin D, a transcription inhibitor
known to affect ribosome production, we observed both an
increase in GFP-SBDS-FL nuclear import as well as nuclear
export in these cells (Fig. 5C/D/G/H). This suggests that SBDS-
FL under steady-state conditions is retained in the nucleus in
transcriptional or ribosomal protein complexes, which are
disrupted upon actinomycin D treatment. Importantly, these data
also provide indirect evidence that GFP-SBDS-FL protein is
functional, since interference with ribosome and RNA processing
affects mobility of the protein.
In contrast to actinomycin D, treatment of cells with the
translation inhibitor cycloheximide did not affect nuclear export
of SBDS. However, an increase in GFP-SBDS-FL nuclear
import rate was observed in the presence of cycloheximide,
suggesting that GFP-SBDS-FL in the cytoplasm is indeed
retained in translation-related protein complexes (Fig. 5B/D/
F/G). Thus, these data underline the physiological evidence of
presented data.
Figure 4. SBDS C-terminus affects intracellular transport. (A) Representative picture of the GFP-SBDS R218, GFP-SBDS-L234 and GFP-SBDS
K225-226R proteins. Bottom panel shows the GFP fluorescence intensity plots measured as indicated in the corresponding cells in the top panel.
White bar represents 10 mm. (B) Average ratio of the nuclear/cytoplasmic GFP fluorescence intensity for the different GFP-tagged constructs. Error bar
indicates s.e.m. (FL n=42 cells, R218 n=33, L234 n=37, K225-226R n=30 cells in 3 independent experiments). (C) Alignment of the C-terminal amino
acid sequence of SBDS-FL, SBDS-R218 and SBDS-L234 revealed a consensus SUMO (YKxE) sequence. (D) Representative Western blot analysis shows
that HA-SBDS-FL can be easily detected in the input lysate and the pull-down samples. In the SUMO-2 pull-down, but not in the SUMO-1 pull-down, a
17 kDa higher molecular isoform of HA-SBDS-FL is present showing that SBDS-FL is modified by SUMO-2 (n=3). (E) FRAP analysis showing the
average nuclear/cytoplasmic GFP ratio for GFP-SBDS-L234 and GFP-SBDS-K225-226R. We analysed 6–9 cells per construct in 3 independent
experiments. (F) FLIP analysis showing the average nuclear GFP intensity for GFP-SBDS-FL, GFP-SBDS-L234 and GFP-SBDS-K225-226R. 7–11 cells per
construct in 2–3 independent experiments were analysed.
doi:10.1371/journal.pone.0020727.g004
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SBDS protein domains dictate subcellular localization
and mobility
Our data has provided interesting insights into the SBDS
protein domains that dictate subcellular localization and mobility.
As indicated schematically in the SBDS protein model (Fig. 6), the
SBDS protein contains three domains: an N-terminal FYSH
domain, a central helix-turn-helix domain and a C-terminal RNA-
recognition motif (RRM) [10,11]. Our studies have identified
three distinct regions within these domains that seem to play a role
in SBDS intracellular localization and/or mobility.
First, in the SBDS N-terminal FYSH domain we observed
nuclear localization activity. Our localization and mobility data
revealed that the GFP-SBDS-K62 and GFP-SBDS-C84 were
localized and retained in the nucleus to a greater extent than free
Figure 5. GFP-SBDS-FL intracellular transport is affected by ribosome and RNA processing inhibitors. (A) Representative GFP-SBDS-FL
and (B) GFP-SBDS-FL-expressing cell in the presence of cyclohexamide (C) GFP-SBDS-FL expressing cell in the presence of actinomycinD for FRAP
analysis prior to bleaching, at the moment of nuclear bleaching and 10 min post-bleach. (D) FRAP analysis showing the average relative nuclear/
cytoplasmic GFP ratio for GFP-SBDS-FL (light grey curve), or GFP-SBDS-FL in the presence of actinomycinD (dark grey curve) or cyclohexamide (black
curve). We analysed 8-9 cells in 2 independent experiments. (E) Representative GFP-SBDS-FL and (F) representative GFP-SBDS-FL expressing cell in the
presence of cyclohexamide and (G) representative GFP-SBDS-FL expressing cell in the presence of actinomycinD for FLIP analysis prior to bleaching,
at the moment of nuclear bleaching and 10 min post-bleach (H) FLIP analysis showing the average nuclear GFP intensity for GFP-SBDS-FL (lightgrey
curve), GFP-SBDS-FL in the presence of cyclohexamide (black curve), GFP-SBDS-FL in the presence of actinomycinD. We analysed 7–12 cells in 3
independent experiments.
doi:10.1371/journal.pone.0020727.g005
Figure 6. SBDS protein model. Model of the SBDS protein based on
our live cell imaging and localization data. Our data suggest that the
SBDS N-terminus contains nuclear localization motifs, that the FYSH
domain contains a potential Nuclear Export Sequence (NES). Further-
more, we have identified a SUMO consensus sequence (YKxE) within
the SBDS C-terminal RNA recognition motif (RRM) that is involved in
regulating SBDS intracellular mobility.
doi:10.1371/journal.pone.0020727.g006
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potential nuclear localization signal (NLS).
Next, we observed nuclear export activity in the FYSH domain
within the region of amino acids 75–85. In our live cell imaging
experiments we observed that exportrate of SBDS D1–75 and SBDS
D1–65 was higher than SBDS D1–85. Also the nuclear-cytoplasmic
ratio of GFP-fluorescence of these GFP-tagged SBDS D1–75 and
SBDS D1–65 was significantly lower as compared to SBDS D1–85.
Together these data suggest that GFP-SBDS D1–65 and D1–75
contain a nuclear export signal (NES) that is lacking in the GFP-
SBDS D1–85. However, analysis of the SBDS amino acid sequence
did not reveal a known consensus nuclear export signal (NES)
sequence. Possibly, so far unidentified, protein-protein interactions
with this SBDS domain could be contributing to enhanced export of
GFP-SBDS D1–75 and SBDS D1–65. Additional studies will be
required to identify the exact amino acid sequence containing this
NES activity and/or the possible protein-protein interactions that
may affect cytoplasmic localization of SBDS.
Finally, our data showed that the SBDS C-terminus is playing a
dominant role in cytoplasmic localization, since deletion of 32
amino acids of the SBDS C-terminus (i.e. SBDS-R218) result in a
prominent nuclear localization. More detailed analysis revealed
that the amino acids R218 to L234 in the SBDS protein were
important for subcellular localization. The SBDS-L234 mutant
protein that lacks the 16 most C-terminal amino acid residues has
a similar subcellular distribution as SBDS-FL, but displays higher
intracellular mobility as compared to SBDS-FL. This suggests that
SBDS amino acids 234–250 play a role in intracellular trafficking,
possibly due to protein-protein interactions or alternatively due to
intramolecular interactions.
SBDS sumoylation regulates intracellular mobility
Post-translational protein modification, including ubiquitination
and sumoylation, is an important reversible cellular mechanism to
change protein function, activity and/or localization [30–35].
Sumoylation of proteins was first reported for RanGAP1 and this
was shown to affect nucleo-cytoplasmic shuttling of the protein
[35]. Currently, 3 different SUMO proteins have been identified
in vertebrates. Progress in finding SUMO substrates has been
hampered by the fact that generally only a small portion of the
protein pool is sumoylated and that SUMO conjugates are rapidly
removed by isopeptidases upon cell lysis [30–34].
We identified by in silico analysis several consensus sumoylation
sites in the SBDS protein of which a YKxE consensus sumoylation
site is located in the SBDS C-terminus. We showed that a fraction
of the SBDS protein pool is sumoylated. Site-directed mutagenesis
destroying this C-terminal sumoylation site resulted in a clear
change in the SBDS protein mobility. Interestingly, SBDS
sumoylation of the mutated SBDS isoforms was decreased, but
not completely abolished, suggesting that other SBDS protein
regions are also sumoylated. Noteworthy is that the patient-
derived SBDS protein variants lack the C-terminal sumoylation
target sequence. It can be speculated that the disturbed protein
motility regulation is contributing to the deregulated SBDS protein
function in SDS-patients.
Live cell imaging studies suggest a role for SBDS related
to ribosomal function
To date, different cellular functions have been proposed for
SBDS, among which are: (1) a role in migration, (2) a role in
mitotic spindle stability and function, and (3) a role in ribosomal
processing and/or transport. Consistent with the proposed role in
migration, Wessels et al. have shown that GFP-SBDS is localized
at the cellular periphery of the leading edge in migrating
Dictyostelium [38]. Moreover, SDS leukocytes were reported to
have a subtle chemotactic dysfunction [5,6,38] as well as F-actin
polymerization and cellular polarization defects [39]. More recent
reports revealed that SBDS is located at the mitotic spindle
[17,18]. Most prominently are the reports showing that SBDS is
biochemically involved in ribosome maturation and/or RNA
processing [10–15,36–38]. The crystal structure of the A. fulgidus
SBDS ortholog revealed that SBDS contains three distinct protein
domains, including possible RNA or DNA interaction motifs
[10,11]. Consistent with this, Menne et al. have shown that the
yeast SBDS ortholog, Sdo1, has a role in ribosome maturation, as
was confirmed for human SBDS [12,15]. Recently, several SBDS
binding partners with diverse molecular functions were identified
using affinity capture and mass spectrometry. These binding
proteins include components of the large ribosomal subunit and
proteins involved in DNA repair [40]. Our data indicate that,
irrespective the preferred binding partner, under steady state
conditions, SBDS seems not to be an efficient shuttling protein
transporting RNA or ribosomal elements from the nucleus to the
cytoplasm or vice versa.
Another nucleolar ribonucleoprotein, nucleophosmin (NPM),
that has been previously proposed to interact with SBDS [15], was
shown to shuttle between the nucleus and cytoplasm in
heterokaryon cellular experiments [41]. To investigate whether
trafficking dynamics of SBDS and NPM, indicative for a protein-
protein interaction, would be similar, we performed live cell
imaging for GFP-NPM. The localization of GFP-NPM was
restricted to the nucleoli and therefore we were unable to perform
live cell imaging experiments for nucleo-cytoplasmic shuttling.
However, we observed that GFP-NPM can move freely between
nucleoli, suggesting that NPM, similar as SBDS, is not
incorporated into large rigid protein complexes (data not shown).
Altogether, in our experiments, SBDS and NPM have strikingly
different intracellular localization, which is not supportive of an
extensive interaction between SBDS and NPM. Interactions with
the aforementioned binding partners from the SBDS-interactome
and following co-immunoprecipitation studies [40] would be of
interest in future studies on co-localization with SBDS in live cell-
imaging studies.
Interestingly, SBDS nuclear export was enhanced upon
blockade of cellular transcription, suggesting that SBDS might
be present in a transient manner in nuclear ribosomal protein
complexes that prevent SBDS transport to the cytoplasm.
Actinomycin D treatment of cells results, besides an inhibition of
transcription, also in a loss of the nucleolar structures. Despite the
fact that we did not commonly observe enriched nucleolar
localization of SBDS, our live cell imaging data suggests that
SBDS is associated with nucleolar complexes, which are disrupted
upon actinomycin D treatment. Also translational inhibition with
cycloheximide affects SBDS nucleo-cytoplasmic transport, again
suggesting that SDBS in the cytoplasm is also interacting with
ribosomal proteins.
In conclusion, our live cell imaging data are consistent with a
cellular role for SBDS in ribosome function as previously proposed
by several studies [10–15,36–38], and are the first to describe at a
molecular biological level the differences in protein characteristics
between full-length SBDS and SDS-patient derived SBDS protein
isoforms.
Materials and Methods
Cell culture and transfections
HeLa cells were cultured in IMDM with 10% FCS, penicillin
(200 mg/ml), streptomycin (200 mg/ml) and L-glutamine (4 mM).
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according to manufacturer’s instructions and analysed 24–
48 hours after transfection.
To disrupt the cytoskeleton cells were treated with either
500 ng/ml nocodazole (Sigma) or with 1 mg/ml cytochalasin D
(Sigma) for 30 minutes prior to live cell imaging. To inhibit
transcription or translation, cells were treated with 50 ng/ml
Actinomycin D (Sigma) or 10 mg/ml cyclohexamide for 2 hours
prior to live cell imaging. Imaging was performed in the presence
of these inhibitors.
Cloning of SBDS transcripts
SBDS was PCR amplified from leukocyte cDNA from healthy
volunteers with the following primers: SBDS forw 59-GAGATCG-
GATCCTCGATCTTCACCCCCACC-39 and SBDS rev 59-GA-
GATCGTCGACTCATTCAAATTTCTCATCTCCT-39. SBD-
S cDAs were cloned into pEGFP-C1 vector (Clontech) or
pCDNA3.1 vector containing a hemagglutinin (HA) tag. Sequenc-
es of the primers that were used to generate SBDS mutant
constructs are listed in Supplementary Table S1. All constructs
described in this manuscript were sequence verified.
Western Blotting and pull-down assays
Cells were lysed with 20 mM Tris-Cl pH 7.4/135 mM NaCl/
1.5 mM MgCl2/1%TritonX-100/10%glycerol in the presence of
protease inhibitors (Complete EDTA-free (Roche)). Proteins were
separated on SDS-PAGE and blotted against PVDF membrane
(Biorad). Blots were blocked and incubated overnight with the
primary antibody followed by incubation with HRP-labelled
secondary antibodies (Amersham) and Enhanced Chemilumines-
cence detection (Pierce).
To detect sumoylated SBDS, Hela cells were co-transfected as
described above with HA-SBDS and 6xHis-tagged Sumo1 or
6xHis-tagged Sumo2. Cells were 24 hours after transfection
washed with PBS (containing Mg
2+ and Ca
2+) at roomtemperature
and lysed for 5 minutes in Urea buffer (20 mM Tris–HCl, pH 7,5
200 mM NaCl,10 mM Imidazol, 0.1% Triton X-100 and 8M
urea). Cells were scraped, collected and incubated for 10 min at
37uC and centrifuged 5 min at 14000x rpm (RT), after which the
supernatant was incubated with 25 ml of prewashed, blocked
(200 mg/ml BSA for 1 hr at roomtemperature) Talon beads
(Clontech) at roomtemperature for 1,5 hr while rotating. Beads
were washed 5 times with Urea buffer and resuspended in Laemlli
sample buffer and boiled for 5 minutes at 95uC. Sumoylated HA-
SBDS-FL was detected by anti-HA Western-blot analysis.
Antibodies used were anti-GFP (JL-8;Clontech), anti-beta-actin
(AC15; Sigma), anti-HA (Y11, Santa Cruz; 12CA5, hybridoma
cells were a kind gift of B.Burgering), anti-SBDS (rabbit polyclonal
[18]) and anti-Sumo antibodies (kind gift from A.Vertegaal).
Immunofluorescence
Cells were grown on glass coverslips and transfected as
described above. Cells were fixed 16–24 hours after transfection
with 4% paraformaldehyde/PBS and permeabilized with NET-
GEL (50 mM Tris pH 7.4/150 mM NaCl/5 mM EDTA/0.05%
NP-40/0.25% gelatine/0.02% NaN3). Cells were stained with the
primary antibody overnight, rinsed with PBS/0.5%Tween,
incubated with an Alexa488 or Alexa543 conjugated secondary
antibodies (Molecular Probes) and counterstained with propidiu-
miodide (PI) or TO-PRO-3 iodide (Molecular Probes) to visualize
the nucleus. Cells were washed with PBS/0.5% Tween and
embedded with Mowiol 4–88 (Calbiochem). Pictures were made
with a Zeiss LSM 510 META CLSM microscope with Zeiss 65x
oil objective at room temperature and processed with LSM 510
and/or Zen 2007 software. GFP intensity was determined with
ImagePro or Zen 2007 software.
Live cell imaging
HeLa cells were grown on 30 mm round Menzel-Glaser glass
coverslips, transfected with indicated GFP-tagged SBDS constructs
as described and used for live cell imaging 16–24 hours after
transfection. Cells were transferred to a POC-mini imaging
chamber (Carl Zeiss) and supplied with phenol red-free
DMEM/F12 (1:1) containing 10% FCS, pencillin and streptomy-
cin. Imaging was performed in a conditioned chamber at 37uC
with 5% CO2 with a Zeiss confocal microscope (LSM 510 META,
Zen 2007 software) and Zeiss 63x oil objective.
General FRAP settings were as follows. The 488 nm laser
output for all the experiments was set at 50% with bleach power at
100% and 5 images of 500 msec were acquired prior to bleaching.
Imaging was performed at 0.5% laser output and 45–445 images
of 500 msec were obtained after bleaching. GFP was measured
with an optical slice of 1 mm.
To determine intra-nuclear SBDS dynamics a rectangle area
(4 mm width) was bleached for 20 iterations and FRAP
measurements were performed for 50 images of 500 msec each.
To determine intra-cytoplasmic SBDS dynamics a circular area
(max 20% of the total cell volume) was bleached for 50 iterations
and FRAP measurements were performed for 50 images of
500 msec each. To determine nuclear import, an oval area that
covers most of the nucleus was bleached for 50 iterations and a
total of 100–250 images of 500 msec each were taken. With Zen
2007 software the average of the absolute fluorescent intensity is
measured for the bleach region, the nucleus, the cytoplasm and the
background. Additionally, GFP intensity in a control cell was
quantified verify that imaging did not cause additional bleaching.
FLIP laser settings for bleaching and imaging are similar for
FRAP, except that a circular bleach region in the cytoplasm
covered a maximum of 20% of the total cell volume. The first
bleach was made after 5 recorded images and bleaching was
repeated after every 10 images of 500 msec each. Bleaching is
performed with 25 iterations per bleach and a total of 250 images
are acquired.
For statistical analysis, background correction was performed.
Each different cellular area was normalized to the initial nuclear
fluorescent intensity by using the average of nuclear intensity of
the 5 images prior to bleaching. Then the average fluorescent
intensity and standard error of the mean (sem) is calculated for
each time point. Results are presented as the relative fluorescent
nuclear/cytoplasm ratio or cytoplasm bleach/cytoplasm non-
bleach ratio.
Supporting Information
Figure S1 HA-tagged SBDS proteins localize in a similar
manner as GFP-SBDS proteins. (A) Schematic overview of
the HA-tagged SBDS constructs (B) Western blot analysis shows
that HA-tagged SBDS proteins have the expected molecular sizes
of 32 kDa, 14 kDa, 28 kDa and 22 kDa for the HA-SBDS-FL,
HA-SBDS-C84, HA-SBDS-R218 and HA-SBDS D1-85 respec-
tively. Upper panel shows anti-HA staining and lower panel actin
staining as a loading control (C) Representative pictures of the
intracellular localization of the HA-tagged SBDS proteins. Upper
panel shows propidiumiodide nuclear staining and bottom panel
shows HA-SBDS staining. White bar represents 10 mm. (D)
Average ratio of the nuclear/cytoplasmic HA fluorescence
intensity for the different HA-tagged constructs. (FL n=30 cells,
C84 n=35 cells, R218 n=33 and D1–85 n=12 cells in 2
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analysis due to the low expression levels.
(TIF)
Figure S2 GFP-SBDS-FL mobility characteristics. (A)
Average of the relative fluorescence intensity of GFP-SBDS-FL
in the nucleus (grey line) and the cytoplasm (black line) during 5
minutes after photobleaching of the nucleus. After photobleaching
the amount of GFP-SBDS-FL in the nucleus and cytoplasm does
not change, showing that there is no nuclear import of GFP-
SBDS-FL. (n=13 cells in 2 independent experiments; error bar
indicates s.e.m.). (B) Average of the relative fluorescence intensity
of GFP-SBDS-FL in the cytoplasm at the photobleach area (black
line; cyto bleach) and in another non-bleached cytoplasmic reveals
that GFP-SBDS-FL fluorescence intensity increases rapidly in the
photobleach area at the expense of GFP-SBDS-FL fluorescence in
other parts of the cytoplasm. Hence, GFP-SBDS-FL is mobile in
the cytoplasm (n=14 cells in 3 independent experiments).
(TIF)
Figure S3 SBDS C-terminus affects intracellular trans-
port. (A) FRAP analysis showing the average nuclear/cytoplasmic
GFP ratio for GFP-SBDS-FL, GFP-SBDS-K225-226R and GFP-
SBDS-E227Q. We analysed 6-13 cells per construct in 2–4
independent experiments. (B) FLIP analysis showing the average
nuclear GFP intensity for GFP-SBDS-FL, GFP-SBDS-K225-
226R and GFP-SBDS-E227Q. 7–11 cells per construct in 2–3
independent experiments were analysed. (C) Average ratio of the
nuclear/cytoplasmic GFP fluorescence intensity for the different
GFP-tagged constructs. Error bar indicates s.e.m. (FL n=21 cells,
K225-226R n=41 cells, E227Q n=24 cells in 2–3 independent
experiments).
(TIF)
Table S1 Primer sequences.
(DOCX)
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